Senior Manager Drug Safety Biotech Boston, great – World leading Biotech firm – Boston, MA

Industry: Biotech/Pharma

Description: World leading Biotech firm seeks East coast based position for… in the pharmaceutical/biotech industry in safety…

From HelpWantedBoston.com – 02 Jun 2010 05:58:52 GMT
– job details
– View all Boston jobs

View full post on biotech Jobs | Indeed.com

Innovative and Targeted Cancer Therapies: Key technologies, new applications and leading players–Aarkstore Enterprise

Aarkstore announce a new report  ” Innovative and Targeted Cancer Therapies: Key technologies, new applications and leading players ” through its vast collection of market research report.

Portfolio of healthcare management reports are designed to help you make well informed and timely business decisions. We understand the problems facing today’s pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions. The strength of our healthcare research and analysis is derived from access to unparalleled databases and libraries of information and the use of proprietary analytic techniques. Business Insights reports are authored by independent experts and contain findings garnered from dedicated primary research. Our authors’ leading positions secure them access to interview key executives and to establish which issues will be of greatest strategic significance for the industry. Our healthcare portfolio of reports can be used across a wide range of business functions to assess market conditions and devise future strategy. Our reports cover key areas including strategy, industry analysis, market outlook, new business opportunities and strategic insight.

Some key findings from this report…

The global market for cancer innovatives has more than trebled in size over the last four years, achieving a compound annual growth rate (CAGR) of 33.1% between 2003 and 2006.

Monoclonal antibodies comprised four of the top ten leading cancer innovatives in 2006, supplemented by novel chemotherapeutics, hormonals and targeted therapies.

Ten ‘blockbuster’ drugs are likely to emerge in cancer therapy over the next decade as recent and impending scientific breakthroughs continue to enhance treatment options.

Mononclonal antibodies will experience a surge in market growth after label extensions into new treatment settings and indications.

Genentech and Roche continue to command a substantial proportion of the cancer innovatives market, generating almost 50% of all sales in 2006.

Innovative and Targeted Cancer Therapies

The highly dynamic cancer market is creating a new age of discovery and innovation driven by molecular biology, oncogenomics and new methods in cell biology. Resultantly, cancer innovatives are not only the fastest growing segment within the cancer market, but the key drivers of sales growth across the pharmaceutical market as a whole. These innovations will result in high value opportunities to develop newer and more effective therapies, ensuring companies can effectively respond to the increasing prevalence of cancer. Innovative and Targeted Cancer Therapies provides a detailed insight into both cancer therapeutics and diagnostics, to provide a clear vision of how the cancer market will develop over the next five years. It also identifies key alliance and partnering opportunities, highlighting companies with specialised capabilities in the discovery and the characterization of next-generation drug targets. Use this report to understand how the cancer market is developing, identify areas of unmet medical need and align your product pipeline to achieve clinical and commercial success.

Top five reasons to order your copy today

Fully understand and assess your organisation’s situation within the evolving market environment, through the identification of innovative cancer classes, products and partnering opportunities.

Exploit under served therapy sectors within the Oncology market more effectively by evaluating the most significant areas of under provision, as identified by this report

Secure the long term success of your portfolio by examining the strategies that can effectively promote new product development and the lifecycle management of innovatives.

Gain detailed competitive intelligence and enhance your strategic outlook by benchmarking the successful strategies employed by the leading companies within the industry.

Synchronize your future offering with the latest developmental plans and forecasts for innovative cancer products, and with the latest changes in the industry’s pricing and regulatory environment.

Key issues examined in this report…

Identification of a significant number of unmet therapeutic needs. These will form the basis of future treatment developments across a variety of cancer types and treatment settings.

Commercial potential of several rapidly evolving product and technology breakthroughs. Particularly consistent of the market interplay between monoclonal antibodies, targeted therapeutics, novel chemotherapies and hormonal treatments.

Application of existing therapies in new treatment settings and indications bearing increasing importance as a facilitator of wider product lifecycle optimization efforts.

Targeted therapies delivering the most effective treatments for selected cancers. Most notably, these include novel kinase inhibitors and other treatment pathways.

Strategic and market positioning of the leading pharma and biotech companies operating within oncology innovatives.

Your questions answered…

Where are the key supply shortfalls in the cancer market?

What are the most significant areas of new growth within cancer innovatives?

Which emerging product innovations harbour the most significant potential in cancer treatment?

Who are the companies pioneering novel therapies, and what strategies do they employ to integrate successful portfolios?

Which key drug and product classes are set to dominate the cancer innovatives market in 2011?

What important factors can provide a synergistic balance between new product launches and lifecycle management?

For more information, please visit :
http://www.aarkstore.com/reports/Innovative-and-Targeted-Cancer-Therapies-Key-technologies-new-applications-and-leading-players-34836.html
Or email us at press@aarkstore.com or call +919272852585

Special offer till 31th Dec 2009

Biomarkers In Late Stage Clinical Trials: Applications, Opportunities And Activities Of Leading Players

The pharmaceuticals and biotechnology sectors are currently facing increasing time and cost issues related to clinical trials in drug discovery. The cost of developing a new drug can reach $2 billion; clinical trials, regulatory approval and subsequent launch may take up to a decade.

Biomarkers reduce the attrition rate of late stage clinical trials by assessing drug potential in terms of efficacy and toxicity at the early stages of the clinical development. Thus, biomarkers significantly increase productivity, lower the cost and duration of the clinical trial, and help researchers complete drug development process at a faster pace.

This report reviews various biomarker technologies and therapy area applications. Market drivers and restraints are viewed in the context of biomarker activity of leading innovator companies as well as contract research organizations.

Key features of this report
• The report analyzes revenues of late stage biomarker technology and services in North America, Europe, Asia and rest of the world.
• Provides key market drivers and restraints of the biomarker market.
• Covers microarrays, immunoassay, LC/MS and GC/MS, flow cytometry, imaging, PCR and services
• Provides patent analysis with respect to competitors and geography.

Scope of this report
• Understand and evaluate the growth potential of emerging technologies.
• Understand biomarker activity in clinical trials of leading market players.
• Gain knowledge about the relative importance of the biomarker late stage clinical trials technologies in the next five years for investment opportunities.
• Learn which therapy areas leading market players in the late stage biomarker clinical trials market.
• Determine the collaborations and partnerships of the major market players.

Key Market Issues
• The pharmaceutical and biotech sectors are currently facing increasing duration and cost issues related to clinical trials in drug discovery.
• Funding from government sources such as the National Institutes of Health (NIH) has not increased significantly over the last few years.
• Late stage failures are much more expensive than early ones.
• The rising demand for better safety data has put a considerable amount of regulatory and economic pressure on pharmaceutical companies.
• The current average approval rate of cancer drugs is as low as 5%, while the development period can reach 15 years.
• More than 50% of clinical trials fail in Phase III due to a host of reasons, greater disease complexity, stiffer clinical endpoints, and the inability of the data to prove drug effectiveness.

Key findings from this report
• The biomarkers in late stage clinical trials market is largest in North American and European region, with Europe having the second largest market.
• North America constitutes the major market share with the immunoassay, flow cytometry and GC/MS and LC/MS having high market growth.
• Caprion proteomics, Applied BioSystems, BG Medicine, Covance, Eli Lilly, Pfizer and Astra Zeneca are some of the major companies engaged in collaborative partnerships in the past three years.
• A number of market players have formed strategic alliances for the development and sharing of technology for biomarker applications in the late stage clinical trials.
• Pharmaceutical companies are focusing mainly on cancer biomarkers for use in late stage (Phase III and IV) clinical trials.

Key questions answered
• How is the biomarker late stage clinical trials market segmented and what will growth be to 2014?
• What are the major technologies that have emerged such as microarrays, PCR, LC/MS and GC/MS?
• In which areas are the companies focusing while forming strategic alliances with other industrial players?
• What is the competitive landscape and what is the strategic focus of innovator companies, CROs and biomarker specialists?
• What applications are pharmaceutical companies focusing on while conducting late stage biomarker clinical trials?

Table of Contents
Biomarkers in Late Stage Clinical Trials
Executive summary 12
Market dynamics 12
Biomarker activity at leading pharma companies 13
Applications of biomarkers in clinical trials 13
Biomarker market for late stage clinical trials by tools and services 14
Company profiles 15

Chapter 1 Market dynamics 18
Chapter 2 Biomarker activity at leading pharma companies 40
Chapter 3 Applications of biomarkers in clinical trials 62
Chapter 4 Biomarker market for late stage clinical trials by tools and services 80
Appendix 147

The Cro Market Outlook: Emerging Markets, Leading Players And Future Trends-Aarkstore Enterprise

However, amongst other resistors, the financial crisis resulted in reduced funding available for biotech companies. This fully updated CRO Market Outlook assesses the market drivers and resistors and predicts the effects of these. The report analyzes the overarching trends in the industry; examines which regions are set to see growth in CRO activity; evaluates the leading CROs; and outlines the future of the industry. The report provides insight into conditions into seven emerging regions including China, India and Latin America. It highlights the evolving business and relationship models between CROs and sponsor companies and enables optimal outsourcing strategy.

Key features of this report

Identifies and analyses the most recent trends and issues in outsourcing clinical R&D

Describes where clinical trials will be conducted in the future

Explores the complexities and the costs of outsourcing R&D to different world regions

Profiles the major international CRO players

Provides a detailed assessment of the current CRO market including market share information and the size/growth of R&D spending

Focuses on emerging CRO markets

Highlights evolving strategies for working with CROs

Examines existing and future CRO business models

Key findings from this report

The total CRO market size is estimated at $20bn in 2008 and expected to grow at an annual rate of 8.5% to reach $35bn through 2015. The market is highly fragmented and the number of CROs worldwide has reached over 1,100 despite continued consolidation.

CROs provide substantial global capacity to drug developers and have become a critical contributor to clinical trial activity. Projects with high CRO involvement are associated with shorter development times.

Of the large, global contract research providers, Quintiles is market leader, with 15% of the global market share, followed by Covance and PPD. The five largest CROs have increased their market share and now hold 55% of the total market.

The leading CROs are commodity full service providers operating on a global scale. They act as one-stop shops for all services, from preclinical through marketing.

The number of clinical studies conducted in Asia, Central and Eastern Europe and Latin America is constantly rising. India and China are the future outsourcing destinations of choice.

CROs and pharmaceutical companies are turning to strategic partnerships to gain a competitive edge in the global business environment.
 
 
  Table of Contents : 
Executive summary
The global contract research organization market
CRO market analysis
Established regions in the global CRO market
Emerging regions in the global CRO market
Leading players in the global CRO market
The future of contract research
Chapter 1 The global contract research organization market
Summary
Introduction
The CRO contribution to drug development
Market overview
Key market drivers
Key market restraints
Conclusions and key findings
Overview of the global CRO market
Total revenue forecasts
Global R&D expenditure and CRO market size
Global clinical development outsourcing
The contribution of CRO to drug development
Current market drivers
Growth of R&D expenditure from biotech and pharma
Cost pressures encourage R&D outsourcing
Long term growth and R&D expenditure of biotechnology companies
Growing regulatory burden and safety concerns
US
EU
Patient recruitment
Increasing number of products in development
The development of biomarkers
Current market restraints
Near term reductions in biotech R&D spending
Growing competition and customer consolidation
New financial realities alter biopharmaceutical outsourcing landscape
Shortage of clinical research personnel
Electronic data capture: a threat to CRO revenue
Key market trends
Globalization
EDC evolution
Strategic alliances
Chapter 2 CRO market analysis
Summary
Introduction
Market conditions
Competitive analysis
Market share analysis
Competitive dynamics
Academic medical centers
Site management organizations
Laboratory analytical services
Non-CRO niche service providers
Conclusion
CRO service models
Introduction
The full service model
SWOT analysis
The niche model
SWOT analysis
Industry strategies
Consolidation: Mergers & acquisitions in the CRO industry
Expanding the continuum of services: vertical integration
Forward integration
Backward integration
Industry challenges
Consolidation within the CRO industry: a threat to close customer relationships
Strategic outsourcing: demonstrating clear value to clients
Co-development: sharing the risk
Chapter 3 Established regions in the global CRO market
Summary
Introduction
The US CRO market
Overview
Drivers of the US CRO market
Challenges of the US CRO market
Competitive dynamics
The CRO market in Western Europe
Overview
Infrastructure and local regulations
Drivers of the CRO market in Western Europe
Challenges of the CRO market in Western Europe
Competitive dynamics
Chapter 4 Emerging regions in the global CRO market
Summary
Introduction
The Central and Eastern European CRO market
Overview
Infrastructure and local regulations
Benefits of outsourcing to CEE
Challenges of outsourcing to CEE
Competitive dynamics
The CRO market in China
Overview
Infrastructure and local regulations
Benefits of outsourcing to China
Challenges of outsourcing to China
Competitive dynamics
The CRO market in India
Overview
Infrastructure and local regulations
Intellectual property
Legislative reforms
Benefits of outsourcing to India
Challenges of outsourcing to India
Competitive dynamics
The CRO market in Latin America
Overview
Infrastructure and local regulations
Argentina
Brazil
Mexico
Benefits of outsourcing to Latin America
Challenges of outsourcing to Latin America
Competitive dynamics
The CRO markets in South Korea and Turkey
Overview
Infrastructure and local regulations
Benefits of outsourcing to South Korea
Challenges of outsourcing to South Korea
Benefits of outsourcing to Turkey
Challenges of outsourcing to Turkey
Competitive dynamics
Chapter 5 Leading players in the global CRO market
Summary
Introduction
The client perspective
Capabilities of leading CROs
Quintiles Transnational Corp
Company profile
Business description
Partnering collaborations and recent deals
Covance
Company profile
Business description
Partnering collaborations and recent deals
PPD Inc.
Company profile
Business description
Partnering collaborations and recent deals
Charles River Laboratories
Company Profile
Business description
Partnering collaborations and recent deals
PAREXEL International
Company profile
Business description
Partnering collaborations and recent deals
ICON plc.
Company profile
Business description
Partnering collaborations and recent deals
MDS Inc
Company profile
Business description
Partnering collaborations and recent deals
Kendle International
Company profile
Business description
Partnering collaborations and recent deals
PRA International
Company profile
Business description
Partnering collaborations and recent deals
PharmaNet Development Group
Company profile
Business description
Partnering collaborations and recent deals
Chapter 6 The future of contract research
Summary
Introduction
The shift towards a strategic model
Emerging markets
Phases I and IV growth activity
Electronic data capture
Biomarkers
Selected acquisitions/partnerships
Conclusion
Key findings and conclusions
Chapter 7 Appendix
Selected bibliography
Index
List of Figures
Figure 1.1: Estimated CRO market ($bn), 2003-2015e
Figure 1.2: Global development expenditure and CRO market forecast ($bn), 2008-2014e
Figure 1.3: CRO usage and number of days by which projects overrun
Figure 1.4: Global pharmaceutical R&D expenditure ($bn), 2000-2014e
Figure 1.5: Number of FDA approvals 1990-2008
Figure 1.6: Comparison of drug development cost estimates
Figure 1.7: Global biotech R&D expenditure ($bn), 2004-2012e
Figure 1.8: Number of products in development by phase 1998-2009
Figure 1.9: CRO/Sponsor relationship models
Figure 2.10: Market share of major players, 2008
Figure 2.11: Typical full service CRO model
Figure 3.12: R&D expenditures of PhRMA members and non-member companies ($bn), 1980- 2009
Figure 3.13: Overall indexed clinical trial costs by region, 2006-2008
Figure 3.14: The European CRO market – revenue forecast ($bn), 2008-2012e
Figure 3.15: Pharmaceutical R&D expenditure in Europe ($bn), 1990-2008
Figure 4.16: Geographic distribution of clinical trials, 2005 to 2009f
Figure 4.17: Clinical trial costs of European countries compared to the UK
Figure 4.18: Comparison of trial registration periods in CEE countries (days)
Figure 4.19: CRO market in China ($m), 2007-2012e
Figure 4.20: China’s capabilities across the value chain
Figure 4.21: India’s capabilities across the value chain
Figure 4.22: Number of clinical trials in Latin America, 2000-2008
Figure 4.23: Clinical trials in South Korea, 2005-2009e
Figure 5.24: Revenue growth of top public CROs in 2007-2008
Figure 5.25: Capabilities of leading CROs, 2009
Figure 6.26: Regional presence of major CROs
Figure 6.27: Attractiveness of selected countries for clinical trials
Figure 6.28: Global numbers of phase IV trials 2006-2009e
Figure 6.29: Electronic data capture market size ($m), 2006E-2012e
Figure 6.30: Clinical trials using predictive biomarkers, 2005-2009
List of Tables
Table 1.1: Functions commonly performed by CROs
Table 2.2: The global R&D outsourcing market: five major segments
Table 2.3: SWOT analysis: the full service model
Table 2.4: SWOT analysis: the niche model
Table 2.5: Key deals in the CRO sector
Table 4.6: Major CROs operating in Eastern Europe, 2009
Table 4.7: Domestic Chinese CROs
Table 4.8: Major domestic CROs operating in Latin America, 2009
Table 4.9: Selected domestic CROs in South Korea and Turkey
Table 5.10: Revenues ($m) and growth of major CROs, 2007-2008  
 

For More information please contact :

http://www.aarkstore.com/reports/The-CRO-Market-Outlook-Emerging-markets-leading-players-and-future-trends-34933.html

US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting …

US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting …
US Oncology, Inc., the nation’s leading integrated oncology company, announced today that a leading group of US Oncology affiliated scientists from the US Oncology Research network met with a select group of leading pharmaceutical companies on April 24 – 25, at the Grand Hyatt DFW in Fort Worth, Texas, for the Fifth Annual Cancer Drug Development Working Group.

Read more on PR Newswire via Yahoo! Finance

Next Page »